Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Aug 15, 2021; 13(8): 772-798
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772
Table 5 Selected retrospective studies reporting prevalence of gastrointestinal immune-related adverse events in inflammatory bowel disease patients treated with all immune checkpoint inhibitor regimens
- Citation: Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798
- URL: https://www.wjgnet.com/1948-5204/full/v13/i8/772.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.772